TEVA FDA decision: Nov 13, 2026 (announced Nov 16)
Page updated ·next FDA decision on the calendar·Data as of Nov 19, 2026 12:24 AM ET
✓ APPROVED
IGALMI (dexmedetomidine sublingual film) was approved by the FDA for at-home agitation in bipolar disorder or schizophrenia (sNDA); the approval was announced on November 16, 2026.
This page was first committed to pdufa.bio's public repository on Nov 17, 2026, 1:24 AM ET (public commit ce46f16). Dates on this page are the FDA's and the sponsor's; this line is ours.
Teva announced on November 16, 2026 that the FDA approved IGALMI (dexmedetomidine) sublingual film for at-home use, the first at-home treatment for agitation associated with schizophrenia, schizoaffective disorder or bipolar I or II disorder in adults.
Run-up into the decision (T-120 → T+0)
Daily close, T-120 (5/27/26) through T+0. Run-up high $44.5 on 11/13/26, low $30.15 on 7/22/26 (T-120 to T-1). Announced 11/16/26 (FDA action 11/13/26). Historical price action, not a forecast.
Key facts
FDA decision date2026-11-13
Announced2026-11-16
OutcomeApproved
Drug / candidateIGALMI (dexmedetomidine) at-home sNDA
IndicationAcute agitation with schizophrenia, schizoaffective disorder or bipolar I/II disorder: at-home use (adults)
CompanyTeva Pharmaceutical Industries
Market-cap tierLarge
120-day run-up (T-120→T-1)+28.6%
Decision-day move-4.3%
Move measured on2026-11-16 close (the announcement day), against the 2026-11-13 close
Cohort decision-day move (history)1.0% median (n=828)
The PDUFA goal date was November 14, 2026 (a Saturday; BioXcel 8-K, May 15, 2026). The FDA's own record dates the action November 13, 2026, 1 day before the goal date; Teva announced it on November 16, 2026.
Run-up figures are the stock's own daily closing path over the 120 trading days before the decision, from our price history. Cohort move is the historical median absolute decision-day move for this market-cap tier. History, not a prediction.
FDA record of the action: the FDA approved on November 13, 2026, per NDA 215390 S-003 (Drugs@FDA). The sponsor announced it on November 16, 2026. Action dates on pdufa.bio come from the FDA's own record, not the press release. Every FDA action we hold, by FDA date: FDA approval letters.
Questions
Was IGALMI (dexmedetomidine) at-home sNDA approved by the FDA?
Yes. The FDA approved the application for IGALMI (dexmedetomidine) at-home sNDA on November 13, 2026, per the FDA's own record. The company announced it on November 16, 2026. The primary source is linked on this page.
Which company is behind IGALMI (dexmedetomidine) at-home sNDA?
IGALMI (dexmedetomidine) at-home sNDA is a Teva Pharmaceutical Industries (TEVA) program. The FDA decision came on November 13, 2026; the company's own announcement is linked on this page.
How did TEVA stock react to the FDA decision?
TEVA moved -4.3%, measured as the 2026-11-16 close (the announcement day) against the 2026-11-13 close. It is one trading day's move, so it can include news other than the decision. Historical measurement, not a prediction, and not investment advice.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent publication with no affiliation with, endorsement by, sponsorship by, or connection to the U.S. Food and Drug Administration or any other government agency. “FDA”, “PDUFA” and all company, drug and ticker names are used descriptively and remain the property of their respective owners.
Informational and educational purposes only. Not investment advice. Nothing on this page is investment, legal, tax or medical advice, or an offer or solicitation to buy or sell any security. pdufa.bio is not a registered investment adviser or broker-dealer and does not recommend trades or publish individual-drug approval probabilities. Verify every date and outcome against primary FDA, SEC or company filings. Data is provided as is, without warranty of any kind, and past behaviour does not predict future outcomes.